Frost & Sullivan releases the 'Independent Market Study on Small Nucleic Acid Drugs'

In recent years, the global pharmaceutical market, especially in China, has been booming. From 2015 to 2019, the compound annual growth rates of the global and Chinese pharmaceutical markets reached 4.6% and 7.5%, respectively. Overall, the evolution trend of global pharmaceutical research and development is from non-targeted drugs to targeted drugs. Since most biomarkers cannot be targeted by small molecule drugs or macromolecular preparations, drug non-friendliness has become a bottleneck in the research and development of these drugs. Therefore, targeted nucleic acid drugs for disease treatment at an even more upstream gene level have emerged as the times require. Small nucleic acid drugs are an important class of targeted nucleic acid drugs, mainly including ASO drugs and siRNA, which act on mRNA to interfere with the expression of target genes, thereby achieving disease treatment. To date, small nucleic acid drugs have undergone about 40 years of development.